Abstract 503P
Background
Circadian fluctuations in T-cell function may modulate the efficacy of immune checkpoint inhibitors (ICIs). An association between time-of-day of ICI infusion and outcomes in patients with advanced non-small cell lung cancer (NSCLC) and melanoma has been reported; however, such association in patients with locally advanced NSCLC remains unclear. We aimed to determine whether durvalumab time-of-day infusion could impact the survival of patients with locally advanced NSCLC.
Methods
We retrospectively analyzed patients with unresectable locally advanced NSCLC treated with chemoradiation and adjuvant durvalumab between January 2018 and May 2022. According to previous research, the receipt of ≥20% vs <20% of infusions after the 15:00h cut-off time was set as the threshold for analysis. We calculated the association between the proportion of durvalumab infusions after 15:00h and survival (PFS [progression-free survival] and OS [overall survival]) using Cox regression.
Results
82 patients were included. The median age was 69 years (IQR, 44–85), 67 patients (82%) were male, 78 (95%) were current or former tobacco smokers, and 79 (96%) had performance status (PS) 0 or 1. Histology was non-squamous for 49 (60%). PD-L1 expression <50% was for 36 (44%). Patients who received at least 20% of durvalumab infusions after 15:00h (12 out of 82, 15%) vs. less than 20% of durvalumab infusions (70 out of 82, 85%) had a statistically significant shorter PFS (median 6.4 months vs not reached, HR: 0.36 [95% CI: 0.16–0.80], P = 0.011) and a trend of shorter OS (median 20.4 months vs not reached, HR: 0.36 [95% CI: 0.21–1.23], P = 0.16). In the multivariate analysis, patients who received at least 20% of durvalumab infusions after 15:00h vs. less than 20% of durvalumab infusions had a statistically significant shorter PFS (HR: 0.38 [95% CI: 0.17–0.88], P = 0.023) and OS (HR: 0.41 [95% CI: 0.16–0.98], P = 0.048).
Conclusions
Time-of-day infusion of durvalumab may impact the survival of patients with locally advanced NSCLC. Although prospective studies of the timing of ICIs are needed, efforts towards scheduling infusions before mid-afternoon might be beneficial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract